LBLiza Benny

Liza Benny

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liza Benny has a total of 120 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A randomized controlled trial of the impact of support visits on self‐isolation compliance: The Havering winter/spring support trial

    by Liza Benny, Cameron Smith, Matthew Barnard, Emily Wolstenholme, Mehr Panjwani, Maria Ionescu, Troy Aitken, Jack Davies, Pete Austin, Lee Watson, et al.

    Objectives: Limited evidence exists on the policies to increase self‐isolation compliance, with no experimental evidence. This trial aimed to evaluate the effect of a home visiting intervention in the London Borough of Havering on compliance with self‐isolation guidance, relative to positive COVID‐19 cases who received no home visits. Design: Mixed method evaluation involving a two‐arm randomized controlled trial (RCT) with an implementation and process evaluation. Methods: A total of 3878 cases who tested positive for COVID‐19 were randomly allocated with equal probability to receive home visits from Havering outreach team staff ( n = 1946) or to a control group ( n = 1932) who did not receive home visits. Randomization was implemented through a spreadsheet consisting of random numbers generated online that was used to randomly allocate cases to treatment and control. Check‐in calls were conducted by a separate blinded contact tracing team on day six of isolation to measure successful self‐isolation compliance. The primary intention‐to‐treat (ITT) analysis was conducted on 3860 cases as 18 patients were excluded from analysis because of the missing outcome data. For the implementation and process evaluation, qualitative, semi‐structured, one‐to‐one interviews were conducted with trial participants in the treatment arm of the RCT ( n = 15) and stakeholders within the London Borough of Havering's Adult Social Care and Health Team ( n = 8). Qualitative data was analysed thematically using a framework approach. Results: Positive cases who were allocated to receive the home visiting intervention ( n = 1933) were more likely to report successful self‐isolation compared to those allocated to the control group ( n = 1927), an effect that was statistically significant (odds ratio 1.204 [95% CI: 1.052, 1.377]; absolute probability difference: 4.1 percentage points [95% CI: 1.2–6.9]). The implementation and process evaluation found that a key driver of compliance was altruistic motivation based on its perceived importance for protecting the community with some participants also reporting the potential of being caught not complying as a driving factor. Participants also reported that the intervention helped them ‘feel supported’, provided them with information about practical and financial support, and clarified their understanding or increased their awareness of self‐isolation and COVID‐19 guidance. No harms were reported from this trial. The trial was registered at the ISRCTN registry, number ISRCTN10030612. Conclusions: A home‐visiting intervention conducted between January and March 2022 increased the self‐isolation compliance of positive COVID‐19 cases allocated to receive home visits. The implementation and process evaluation highlighted that the intervention increased individuals' motivation to comply with guidance, and addressed some barriers associated with opportunity and capability to comply. This trial provides much‐needed evidence to inform the policy and intervention design to support public health and social measures in future outbreak scenarios.

  • Open Access

    A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

    by Thomas Starkey, Maria C. Ionescu, Michael Tilby, Martin Little, Emma Burke, Matthew W. Fittall, Sam Khan, Justin K. H. Liu, James R. Platt, Rosie Mew, et al.

    Patients with cancer are at increased risk of hospitalisation and mortality following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the SARS-CoV-2 phenotype evolution in patients with cancer since 2020 has not previously been described. We therefore evaluated SARS-CoV-2 on a UK populationscale from 01/11/2020-31/08/2022, assessing case-outcome rates of hospital assessment(s), intensive care admission and mortality. We observed that the SARS-CoV-2 disease phenotype has become less severe in patients with cancer and the non-cancer population. Case-hospitalisation rates for patients with cancer dropped from 30.58% in early 2021 to 7.45% in 2022 while case-mortality rates decreased from 20.53% to 3.25%. However, the risk of hospitalisation and mortality remains 2.10x and 2.54x higher in patients with cancer, respectively. Overall, the SARS-CoV-2 disease phenotype is less severe in 2022 compared to 2020 but patients with cancer remain at higher risk than the non-cancer population. Patients with cancer must therefore be empowered to live more normal lives, to see loved ones and families, while also being safeguarded with expanded measures to reduce the risk of transmission.


  • Open Access

    COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study

    by Lennard Y.W. Lee, Maria C. Ionescu, Thomas Starkey, Martin Little, Michael Tilby, Arvind R. Tripathy, Hayley S. Mckenzie, Youssra Al-Hajji, Nathan Appanna, Matthew Barnard, et al.


  • Open Access

    Growth trajectories from conception through middle childhood and cognitive achievement at age 8 years: Evidence from four low- and middle-income countries

    by Andreas Georgiadis, Liza Benny, Benjamin T. Crookston, Le Thuc Duc, Priscila Hermida, Subha Mani, Tassew Woldehanna, Aryeh D. Stein, Jere R. Behrman